|
| 米非司酮用于治疗妇产科疾病的临床效果探讨 |
| The clinical effect of mifepristone in the treatment of obstetrics and gynecology diseases |
| 投稿时间：2020-08-31 修订日期：2020-08-31 |
| 中文关键词: 米非司酮 妇产科疾病 临床疗效 |
| 英文关键词: Mifepristone Obstetrics and Gynecology Clinical efficacy |
|
| 摘要点击次数: 152 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探究妇产科疾病采用米非司酮治疗的效果。方法：将我院自2019年6月至2020年6月期间收治的74例妇产科疾病患者通过计算机表法分为试验组与参照组,两组均纳入37例患者,给予参照组行常规治疗,给予试验组在参照组基础上实施米非司酮治疗,对比试验组与参照组临床疗效及疾病复发情况。结果：试验组治疗总有效率为97.30%明显优于参照组的83.78%(X2=3.9446,P=0.0470),其妇产科疾病在3个月内复发率为8.11%低于参照组的32.43%(X2=6.4021,P=0.0113),妇产科疾病在6个月内复发率为0.00%低于参照组的10.81%(X2=4.2286,P=0.0397),统计学存在研究意义。结论：妇产科疾病给予米非司酮治疗可改善患者临床症状,提升临床疗效,且有效降低复发率,值得应用推广。 |
| 英文摘要: |
| Objective: To explore the effect of mifepristone treatment for obstetrics and gynecology diseases. Method: The 74 patients with obstetrics and gynecology who were admitted to our hospital from June 2019 to June 2020 were divided into the experimental group and the reference group by computer table method. Both groups included 37 patients, and the reference group was given routine routine For treatment, the experimental group was given mifepristone treatment on the basis of the reference group, and the clinical efficacy and disease recurrence of the experimental group and the reference group were compared. Results: The total effective rate of treatment in the experimental group was 97.30%, which was significantly better than 83.78% in the reference group (X2=3.9446, P=0.0470). The recurrence rate within 3 months was 8.11%, which was lower than 32.43% in the reference group (X2=6.4021, P=0.0113). Obstetrics and gynecology diseases within 6 months The recurrence rate was 0.00% lower than the 10.81% of the reference group (X2=4.2286, P=0.0397), which is statistically significant. Conclusion: Mifepristone treatment for obstetrics and gynecology diseases can improve patients' clinical symptoms, enhance clinical efficacy, and effectively reduce the recurrence rate. It is worthy of application and promotion.
发送反馈
历史记录 |
|
View Fulltext
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
